Bococizumab (PF-04950615;RN316)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heterozygous Familial Hypercholesterolemia

Conditions

Heterozygous Familial Hypercholesterolemia

Trial Timeline

Oct 23, 2013 → Apr 15, 2016

NCT ID

NCT01968980

About Bococizumab (PF-04950615;RN316)

Bococizumab (PF-04950615;RN316) is a phase 3 stage product being developed by Pfizer for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01968980. Target conditions include Heterozygous Familial Hypercholesterolemia.

What happened to similar drugs?

1 of 14 similar drugs in Heterozygous Familial Hypercholesterolemia were approved

Approved (1) Terminated (1) Active (13)

✅PraluentSanofiApproved

🔄AZD0780 + PlaceboAstraZenecaPhase 3

🔄Anacetrapib + Placebo for anacetrapibMerckPhase 3

🔄InclisiranNovartisPhase 3

🔄Inclisiran + PlaceboNovartisPhase 3

🔄FluvastatinNovartisPhase 3

🔄Inclisiran + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01968980	Phase 3	Completed	Oct 23, 2013	Apr 15, 2016	Heterozygous Familial Hypercholesterolemia
NCT01968954	Phase 3	Completed	Oct 1, 2013	Apr 1, 2016	Hyperlipidemia

Competing Products

18 competing products in Heterozygous Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Fluvastatin	Novartis	Phase 3	40
Inclisiran + Placebo	Novartis	Phase 3	47
Evolocumab + Placebo	Amgen	Phase 3	40
Atorvastatin + Atorvastatin	Pfizer	Phase 1	29
IBI306 + placebo	Innovent Biologics	Phase 3	40
Lumacaftor Plus Ivacaftor Combination + Ivacaftor	Vertex Pharmaceuticals	Phase 3	40
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo	Sanofi	Phase 3	40
Placebo + Alirocumab	Sanofi	Phase 3	40
Praluent	Sanofi	Approved	35
AK102 + Placebo + Statins and/or Ezetimibe	Akeso	Phase 2	35
lerodalcibep	Medpace	Phase 3	37
mipomersen sodium + placebo	Ionis Pharmaceuticals	Phase 3	37
MGL-3196 (resmetirom) + Placebo	Madrigal Pharmaceuticals	Phase 2	32